EPISODE · Jun 8, 2026 · 21 MIN
Why Amylin May Be the Most Important Weight Loss Hormone You've Never Heard Of
from The Metabolic Classroom with Dr. Ben Bikman
📢 Ask Dr. Bikman’s Digital Mind (multilingual):https://benbikman.com/ben-bikmans-digital-ai-mind📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.comTopic:Amylin is an insulin-sparing satiety hormone released with insulin that slows digestion, restrains glucagon, and helps reduce post-meal glucose spikes. New amylin-based therapies, especially when combined with GLP-1 drugs, may offer powerful weight-loss effects by restoring natural fullness signals rather than forcing insulin higher.Summary:In this lecture, Dr. Bikman explains amylin, a hormone released from the pancreatic beta cell alongside insulin. While insulin helps move nutrients into tissues, amylin works mainly through the brain and digestive tract to increase fullness, slow gastric emptying, restrain post-meal glucagon, and reduce blood sugar spikes without forcing insulin higher. This makes amylin an insulin-sparing hormone and a natural complement to GLP-1.Ben explains why amylin was difficult to turn into a drug: human amylin naturally tends to misfold and form amyloid deposits in the pancreas. Protein engineering solved this problem by creating analogs that activate the amylin receptor without clumping. The first amylin-based drug, pramlintide, proved the concept by reducing appetite, slowing digestion, blunting post-meal glucose rises, and producing modest weight loss, though its short duration and nausea limited broader use.The lecture then moves into newer amylin-based therapies, especially cagrilintide and the combination drug CagriSema, which pairs cagrilintide with semaglutide. Because amylin and GLP-1 work through overlapping but distinct brain pathways, the combination produces greater weight loss than either hormone strategy alone. The takeaway is that amylin may become one of the most important next-generation targets in metabolic medicine because it supports satiety and glucose control without driving insulin higher.References:For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.comNOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
📢 Ask Dr. Bikman’s Digital Mind (multilingual):https://benbikman.com/ben-bikmans-digital-ai-mind📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.comTopic:Amylin is an insulin-sparing satiety hormone released with insulin that slows digestion, restrains glucagon, and helps reduce post-meal glucose spikes. New amylin-based therapies, especially when combined with GLP-1 drugs, may offer powerful weight-loss effects by restoring natural fullness signals rather than forcing insulin higher.Summary:In this lecture, Dr. Bikman explains amylin, a hormone released from the pancreatic beta cell alongside insulin. While insulin helps move nutrients into tissues, amylin works mainly through the brain and digestive tract to increase fullness, slow gastric emptying, restrain post-meal glucagon, and reduce blood sugar spikes without forcing insulin higher. This makes amylin an insulin-sparing hormone and a natural complement to GLP-1.Ben explains why amylin was difficult to turn into a drug: human amylin naturally tends to misfold and form amyloid deposits in the pancreas. Protein engineering solved this problem by creating analogs that activate the amylin receptor without clumping. The first amylin-based drug, pramlintide, proved the concept by reducing appetite, slowing digestion, blunting post-meal glucose rises, and producing modest weight loss, though its short duration and nausea limited broader use.The lecture then moves into newer amylin-based therapies, especially cagrilintide and the combination drug CagriSema, which pairs cagrilintide with semaglutide. Because amylin and GLP-1 work through overlapping but distinct brain pathways, the combination produces greater weight loss than either hormone strategy alone. The takeaway is that amylin may become one of the most important next-generation targets in metabolic medicine because it supports satiety and glucose control without driving insulin higher.References:For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.comNOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Why Amylin May Be the Most Important Weight Loss Hormone You've Never Heard Of
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.